General Topadur’s Phase 2a trial of TOP-N53 for systemic sclerosis-associated digital ulcers advances to next dose levelsBy Healthcare Propulsion StaffNovember 5, 20260 Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced that the Safety Review Committee of its Phase 2a trial…
